| Autor: |
Andrade, Augusto F., Borges, Kleiton S., Castro-Gamero, Angel M., Silveira, Vanessa S., Suazo, Veridiana K., Oliveira, Jaqueline C., Moreno, Daniel A., Queiroz, Rosane G. de Paula, Scrideli, Carlos A., Tone, Luiz G. |
| Zdroj: |
Anti-Cancer Drugs; January 2014, Vol. 25 Issue: 1 p72-81, 10p |
| Abstrakt: |
Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in childhood. Despite the advances in treatment, about 20 of patients relapse andor die, indicating the need for different therapies for this group. Zebularine (ZB) is a potent DNA methyltransferase (DNMT) inhibitor and has been associated with gene demethylation and enhancement of tumor chemosensitivity. This study aimed to evaluate the effects of ZB, alone or combined with chemotherapeutics (methotrexate and vincristine), on childhood ALL cell lines. Cell proliferation, apoptosis, and clonogenic capacity were studied in Jurkat and ReH cell lines. Bisulfite modification, followed by methylation-specific PCR was carried out to evaluate aryl hydrocarbon receptor (AhR) methylation status. Gene expression of DNMT1, DNMT3a, DNMT3b, and AhRwas assessed using qRT-PCR. Both cell cultures were sensitive to ZB, showing a dose-dependent and time-dependent response (P<0.05). ZB induced apoptosis and decreased clonogenic capacity in both cell lines. Combination with methotrexate resulted in a strong synergistic effect, whereas combination with vincristine led to an antagonistic response in both cell lines. ZB treatment decreased gene expression of the three DNMTs and induced AhRgene promoter demethylation and its re-expression. These results indicate that ZB may be a promising drug for the adjuvant treatment of ALL, mainly when combined with methotrexate. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
